Posted by Michael Wonder on 30 Jun 2016
Agenda for the 6 July 2016 TC meeting
30 June 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products.
The Commission will review brivaracetam (Briviact), ulipristal acetate (Esmya), entecavir monohydrate (Baraclude), immunoglobulin (human) (Tegeline), emtricitabine with tenofovir alafenamide fumarate (Descovy), capsaicin (Qutenza) & aflibercept (Eylea).
